Cytokine signaling and resistance to CDK4/6 inhibitors in HR+HER2− breast cancer
While CDK4/6 inhibitors improved clinical outcomes in HR+HER2- metastatic breast cancer (MBC), resistance invariably occurs. The underlying molecular mechanisms are not actionable, leaving limited therapeutic options for progressing patients. Recent data highlight a role for IL-6 in the resistance o...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Nature Portfolio
2025-10-01
|
| Schriftenreihe: | npj Precision Oncology |
| Online-Zugang: | https://doi.org/10.1038/s41698-025-01108-z |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|